에 대한 최신 뉴스 Sage Therapeutics (NASDAQ:SAGE) 주식

Sage Therapeutics

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Global

ALLK

BIIB

CSCO

JNPR

MSFT

ORCL

RBLX

SAGE

SMIN

TYO:5401

TYO:5481

ULCC

WELL

신규 블록 세이지 테라퓨틱스(NASDAQ:SAGE)는 주주들을 만족시키기 위한 &#34;전략적 대안&#34;을 공식적으로 탐색하고 있다. 이 과정에는 가능한 사업 결합부터 전면적인 매각까지 모든 것이 포함된다.

딜 디스패치: 세이지와 실버스가 매각 중, 미스터비스트가 틱톡을 위해 20억 달러를 확보

News

ABBV

LNTH

NGVT

NPSCY

RVNC

SANW

SLRX

TMUS

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 비폭력 마약 범죄자 석방를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다. AP 통신에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 트럼프의 취임식 하루 전이다.

딜 디스패치: 바이든이 틱톡 금지를 트럼프에게 넘기고, 또 다른 유명 소매업체 파산

Sage Therapeutics Inc

SAGEN MI CDA INC PFD A by SAGEN MI CDA INC.

Sage Gold Inc

Sage Group (The) PLC

SAGE GROUP UNSP/ADR by Sage Group plc (The)

Sage Potash Corp

Scotiabank analyst George Farmer maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Sector Outperform and lowers the price target from $14 to $12.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $12

Wedbush analyst Laura Chico reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and maintains $6 price target.

Reiteration

Wedbush Reiterates Neutral on Sage Therapeutics, Maintains $6 Price Target

Throughout the last three months, 7 analysts have evaluated Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, and a low estimate of $4.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 28.72%. 
<img src="https://www.benzinga.com/files/images/story/2025/1739368825_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Sage Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sage Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Sage Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sage Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Sage Therapeutics</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Understanding the Numbers: Sage Therapeutics's Finances</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Sage Therapeutics showcased positive performance, achieving a revenue growth rate of 337.08% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Sage Therapeutics's net margin excels beyond industry benchmarks, reaching -788.06%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sage Therapeutics's ROE excels beyond industry benchmarks, reaching -15.86%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Sage Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -14.18%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Sage Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts

Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $9 to $8.

Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $8

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $14 to $12.

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Lowers Price Target to $12

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Hold to Hold.

Needham Reiterates Hold on Sage Therapeuticsto Hold

Earnings

Earnings Misses

Sage Therapeutics Q4 2024 GAAP EPS $(1.56) Misses $(1.43) Estimate, Sales $12.815M Miss $14.441M Estimate

Biotech giant Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) is scheduled to report fourth-quarter earnings on 12 February.
The Wall Street forecasts fourth-quarter adjusted EPS of $3.35 and sales of $2.40 billion, while fiscal year 2024 adjusted EPS is expected to be $16.34 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $9.64 billion</a>.
January 2025 had been an eventful month for Biogen. Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) announced that its Board of Directors initiated a process to explore strategic alternatives and rejected the unsolicited, nonbinding proposal it received from Biogen for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43232552/sage-therapeutics-board-of-directors-initiates-review-of-strategic-alternatives-and-rejects-biogen" rel="noreferrer noopener">$7.22 per share</a>.
In January, the FDA approved the Supplemental marketing application for lecanemab-irmb (Leqembi) intravenous (IV) maintenance dosing once <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43219641/fda-approves-leqembi-lecanemab-irmb-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-di" rel="noreferrer noopener">every four weeks</a>.
Leqembi is indicated for Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease. After 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued.
The FDA and the European Medicines Agency accepted to review supplemental marketing applications seeking approval for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA).
The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every 4 months, compared to the approved <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43156759/fda-and-ema-accept-applications-for-higher-dose-regimen-of-nusinersen-in-sma" rel="noreferrer noopener">nusinersen regimen (Spinraza)</a>.&nbsp;
The European Commission asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in November 2024, whether this may require an update of the opinion, and whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation. These will be discussed at the CHMP <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43380334/update-on-regulatory-review-of-lecanemab-for-early-alzheimers-disease-in-the-european-union" rel="noreferrer noopener">meeting in February 2025</a>.
Investors are focused on Biogen's growth strategies. This includes expanding its pipeline, pursuing external business development, or leveraging new opportunities to counter declining revenue in the latter&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say" rel="noreferrer noopener">half of the decade</a>.
In December, Jefferies&nbsp;downgraded&nbsp;Biogen, citing the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown" rel="noreferrer noopener">company's tough setup</a>.
Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.
Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible patients continue to hinder adoption.
Price Action: BIIB stock is down 2.61% at $138.81 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43633084/communications-firm-anterix-initiates-strategic-review-with-morgan-stanley-stock-surges" target="_blank" rel="noreferrer noopener">Communications Firm Anterix Initiates Strategic Review With Morgan Stanley, Stock Surges</a></li>
</ul>

Biotech

Large Cap

Guidance

Health Care

Previews

General

What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?

<h3>Companies Reporting Before The Bell</h3>
• Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is estimated to report quarterly earnings at $1.05 per share on revenue of $743.60 million. 
• AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is likely to report quarterly earnings at $4.26 per share on revenue of $6.81 billion. 
• Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is estimated to report quarterly loss at $2.12 per share on revenue of $28.84 billion. 
• Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $5.20 billion. 
• DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is projected to report quarterly earnings at $0.98 per share on revenue of $3.07 billion. 
• BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $45.65 billion. 
• Yatra Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTRA#NASDAQ">YTRA</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $15.02 million. 
• NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $217.60 million. 
• OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $48.93 million. 
• Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) is estimated to report quarterly loss at $1.04 per share on revenue of $59.49 million. 
• Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) is expected to report quarterly loss at $0.01 per share on revenue of $26.52 million. 
• Jerash Holdings (US) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRSH#NASDAQ">JRSH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $37.65 million. 
• Ceragon Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $105.16 million. 
• SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $202.91 million. 
• Curbline Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $28.88 million. 
• IPG Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $229.47 million. 
• LCI Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $799.81 million. 
• Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) is likely to report quarterly loss at $0.07 per share on revenue of $10.50 million. 
• Sunoco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $5.92 billion. 
• WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $650.00 million. 
• Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $2.63 billion. 
• Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) is likely to report quarterly earnings at $2.36 per share on revenue of $6.39 billion. 
• MYT Netherlands Parent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $217.77 million. 
• Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $2.73 billion. 
• WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $5.42 billion. 
• TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $463.18 million. 
• USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $242.95 million. 
• S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) is projected to report quarterly earnings at $3.41 per share on revenue of $3.46 billion. 
• Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $10.70 billion. 
• Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) is projected to report quarterly earnings at $2.27 per share on revenue of $4.13 billion. 
• Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $1.84 billion. 
• GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $1.83 billion. 
• Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) is expected to report quarterly earnings at $1.81 per share on revenue of $4.03 billion. 
<h3>Companies Reporting After The Bell</h3>
• Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is likely to report quarterly earnings at $1.70 per share on revenue of $7.15 billion. 
• Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) is projected to report quarterly earnings at $1.06 per share on revenue of $129.03 million. 
• Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) is projected to report quarterly loss at $1.03 per share on revenue of $2.73 billion. 
• Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) is projected to report quarterly loss at $0.07 per share on revenue of $30.83 million. 
• Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is projected to report quarterly earnings at $0.55 per share on revenue of $1.49 billion. 
• Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $5.78 billion. 
• Evolution Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EPM#AMEX">EPM</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $22.73 million. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $144.62 million. 
• Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) is projected to report quarterly loss at $0.16 per share on revenue of $6.59 million. 
• Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) is expected to report earnings for its fourth quarter. 
• United Fire Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFCS#NASDAQ">UFCS</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $327.70 million. 
• Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $15.62 million. 
• HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $28.48 million. 
• Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) is likely to report quarterly loss at $0.14 per share on revenue of $500 thousand. 
• Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) is projected to report quarterly loss at $1.38 per share on revenue of $14.11 million. 
• Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $562.72 million. 
• Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $106.25 million. 
• BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $168.10 million. 
• Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) is likely to report quarterly earnings at $4.90 per share on revenue of $766.63 million. 
• Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) is likely to report quarterly earnings at $1.91 per share on revenue of $765.40 million. 
• Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $15.30 million. 
• W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $397.32 million. 
• Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $883.43 million. 
• Pitney Bowes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $509.65 million. 
• America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $12.27 billion. 
• Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $3.13 billion. 
• Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) is expected to report quarterly loss at $0.24 per share on revenue of $45.84 million. 
• Anterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>) is expected to report quarterly loss at $0.61 per share on revenue of $1.88 million. 
• IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $934.31 million. 
• Mercury General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $1.23 billion. 
• American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) is expected to report quarterly earnings at $1.53 per share on revenue of $6.70 billion. 
• Diodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $337.10 million. 
• Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) is projected to report quarterly loss at $0.01 per share on revenue of $1.55 billion. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $532.04 million. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $533.26 million. 
• Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $417.67 million. 
• DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $85.54 million. 
• Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $65.48 million. 
• OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $128.13 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $245.02 million. 
• Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $181.92 million. 
• Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is projected to report quarterly earnings at $1.12 per share on revenue of $2.12 billion. 
• Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $80.90 million. 
• Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) is projected to report quarterly earnings at $0.53 per share on revenue of $209.12 million. 
• Gladstone Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLAD#NASDAQ">GLAD</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $24.40 million. 
• InvenTrust Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $71.16 million. 
• Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $254.21 million. 
• Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $21.43 million. 
• Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $491.36 million. 
• Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) is likely to report quarterly earnings at $3.51 per share on revenue of $3.08 billion. 
• Acadia Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $83.33 million. 
• Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) is estimated to report quarterly earnings at $4.58 per share on revenue of $2.22 billion. 
• Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $203.87 million. 
• Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $189.30 million. 
• DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $2.84 billion. 
• Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is projected to report quarterly earnings at $1.03 per share on revenue of $156.13 million. 
• Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $256.84 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADPT

ALSN

ANGI

ARVN

ATEX

ATOM

Brighthouse Financial, Inc. - Common Stock

BIOX

CARR

CFLT

CRNT

CURB

DASH

DIOD

ELMD

EXEL

FORR

FRSH

GILD

GLAD

GNSS

HIVE

IPGP

JRSH

LCII

LDOS

LYFT

MCRI

MYTE

OESX

RPRX

SHOP

SMCI

SMWB

SPGI

SQNS

TYGO

UFCS

UPST

USAC

YTRA

Earnings Scheduled For February 11, 2025

<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Sage Therapeutics, Inc. NASDAQ: SAGE) is officially exploring "strategic alternatives" to make shareholders happy. The process includes anything from a possible business combination to a full-on sale. Who&#8217;s interested? That would be Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), which submitted an unsolicited offer Sage rejected. Cambridge, Massachusetts-based Sage is known for its ZURZUVAE treatment for women with PPD. Goldman Sachs is providing financial advice and Skadden, Arps, Slate, Meagher &amp; Flom LLP oversees legal matters. </li>
<li>Silvus Technologies, a Los Angeles-based mobile telecom owned by TJC, hired Morgan Stanley to explore a sale or initial public offering. TJC could seek a valuation of as much as $5 billion for Silvus, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-30/tjc-is-said-to-weigh-sale-ipo-of-radio-tech-provider-silvus">reported</a> citing sources. TJC, aka The Jordan Company purchased Silvus in December 2019. </li>
<li>Allakos Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) is shutting down its AK006 program, leading to a major downsizing — about 75% of the company will be laid off. The biotech plans to keep around 15 employees to explore strategic alternatives, which CEO Robert Alexander described as "the usual things," according <a href="https://www.fiercebiotech.com/biotech/allakos-axes-program-lays-75-staff-and-seeks-strategic-alternatives-after-phase-1-flop">to</a> Fierce Biotech. The move will significantly deplete Allakos' cash reserves, which stood at $81 million at the end of last year. The company expects to spend $34 million to $38 million on severance and restructuring costs, leaving it with just $35 million to $40 million in reserves by mid-year. The pressure is on to find a new strategic direction quickly.</li>
</ul>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>YouTube star Jimmy Donaldson (aka MrBeast) has secured more than <a href="https://www.benzinga.com/25/01/43325891/backed-by-youtube-king-mrbeast-group-of-american-investors-including-roblox-ceo-lock-in-over-20-billion-for-tiktok-takeover-but-they-have-not-heard-back-directly-from-bytedance">$20 billion</a> for a TikTok offer. An investor group, led by tech entrepreneur Jesse Tinsley, includes Roblox Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) CEO David Baszucki and Anchorage Digital CEO Nathan McCauley as investors. Tinsley <a href="https://www.bloomberg.com/news/articles/2025-01-29/tiktok-bidders-to-offer-significantly-more-than-20-billion?sref=KkPzpZvz">told</a> Bloomberg that their offer is &#8220;significantly higher&#8221; than a competing $20 billion bid. Whether Tinsley was referring to the <a href="https://www.benzinga.com/general/entertainment/25/01/42834240/kevin-oleary-joins-the-peoples-bid-for-tiktok-as-pending-ban-looms">Project Liberty bid</a> by former Los Angeles Dodgers owner Frank McCourt and &#8220;Shark Tank&#8221; star Kevin O'Leary is unclear. Also uncertain is whether Microsoft was seriously making a bid, <a href="https://www.benzinga.com/25/01/43260646/microsoft-eyes-tiktok-us-deal-as-trump-confirms-acquisition-talks-are-underway">as indicated by President Trump</a>.</li>
</ul>
<ul>
<li>Hewlett Packard Enterprise&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) $14 billion purchase of Juniper Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) hit a roadblock. The Department of Justice is suing the tech company in what marks the first antitrust action of Trump's second term. The deal would result in Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and the combined HPE-Juniper entity controlling 70% of the wireless networking industry, regulators <a href="https://www.wsj.com/politics/policy/justice-department-sues-to-block-hewlett-packard-enterprises-bid-for-juniper-networks-99af47ac?mod=deals_news_article_pos1&amp;utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=newsletter_axiosprorata&amp;stream=top">said</a>. The merger, which was announced last January, has already received U.K. and EU regulatory approvals. </li>
<li>President Vladimir Putin signed a decree allowing Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to sell its Russia subsidiary to Balchug Capital.<a href="https://link.axios.com/click/38421266.59136/aHR0cHM6Ly9heGlvcy5saW5rLzQweWRrelk_dXRtX3NvdXJjZT1uZXdzbGV0dGVyJnV0bV9tZWRpdW09ZW1haWwmdXRtX2NhbXBhaWduPW5ld3NsZXR0ZXJfYXhpb3Nwcm9yYXRhJnN0cmVhbT10b3A/5841ec813f92a47b9bba9e4dBd37e415e" target="_blank" rel="noreferrer noopener"> </a>The deal makes the U.S. bank one of the few Western banks to fully exit the country, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-31/putin-allows-goldman-sachs-to-sell-its-business-in-russia?srnd=phx-deals">reports</a>.</li>
</ul>
<ul>
<li>Nippon Steel (TYO:<a class="ticker" href="https://www.benzinga.com/stock/TYO:5401#TYO">5401</a>) launched a $456 million tender offer for the remainder of its subsidiary Sanyo Special Steel (TYO:<a class="ticker" href="https://www.benzinga.com/stock/TYO:5481#TYO">5481</a>), representing a 37% premium.</li>
</ul>
<ul>
<li>Outbrain Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) <a href="https://www.wsj.com/business/deals/outbrain-teads-1-billion-merger-deal-cleared-by-u-k-antitrust-regulator-dbc95d74?mod=deals_news_article_pos1">received</a> U.K. antitrust approval for its $1-billion acquisition of Dutch digital advertising platform from Altice, according to the Wall Street Journal.</li>
</ul>
<ul>
<li>Welltower Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) <a href="https://welltower.com/investors/press-release-details/?id=27351#xd_co_f=YTg5NDI3NDMtNjI0Yy00MWUzLTllMDctNDQwMjQxZTliMTg3~">acquired</a> NorthStar Healthcare Income, a New York-based real estate investment trust focused on senior housing, for $900 million.</li>
</ul>
<ul>
<li>Emerson Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>), an automation technology provider, has agreed to acquire the remaining shares it doesn't own of software supplier AspenTech for $265 per share in an all-cash tender offer. The minority stake being now acquired is <a href="https://www.benzinga.com/news/large-cap/25/01/43229951/emerson-electric-to-buy-out-aspentech-minority-stake-in-7-2-billion-cash-deal">valued at $7.2 billion</a>.</li>
</ul>
<h2 class="wp-block-heading">Off The Block</h2>
<ul>
<li>General Mills Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) completed the $2.1 billion sale of its U.S. and Canadian yogurt units to French dairies Groupe Lactalis and Sodiaal.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
<ul>
<li>Spirit Airlines rejected a $400 million merger proposal from Frontier Group Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>). The offer wasn&#8217;t high enough, the bankrupt air carrier said. Spirit, considered the biggest U.S. budget airline, filed a Chapter 11 <a href="https://www.benzinga.com/24/11/42032477/spirit-airlines-eyes-financial-stability-with-chapter-11-filing-and-equity-injection">bankruptcy petition in November</a>.</li>
</ul>
For last week&#8217;s <a href="https://www.benzinga.com/news/asset-sales/25/01/43216373/deal-dispatch-lovely-day-to-sell-guinness-plus-23andme-to-rid-lineage-of-lemonaid">Deal Dispatch, click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/01/43396354/inflation-rises-again-may-be-end-of-the-road-for-interest-rate-cuts-expert-says">Inflation Rises Again: May Be &#8216;End Of The Road&#8217; For Interest Rate Cuts, Expert Says</a></li>
</ul>

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok

Company Board Concludes the Proposal Significantly Undervalues Sage and Believes it is Not in the Best Interest of Shareholders
The Company Remains Focused on the Goal of Establishing ZURZUVAE as the Standard of Care for Women with Postpartum Depression

Sage Therapeutics Initiates Review Of Strategic Alternatives; Rejects Biogen's Unsolicited Acquisition Proposal

President Joe Biden prioritized <a href="https://www.benzinga.com/markets/cannabis/25/01/43054504/biden-commutes-sentences-of-nearly-2500-convicted-of-non-violent-drug-offenses-no-mention-of-cannabis-prisoners">freeing non-violent drug offenders</a> during his final few days in the White House, but TikTok? That's President-elect Donald Trump's problem now. 
According to the <a href="https://apnews.com/article/tiktok-ban-trump-executive-order-1e95d9836bf6f8c0c245ed1c3234d968">Associated Press</a>, Biden has no intention of enforcing the ban, which takes effect on his last full day in office, Jan. 19, and one day <a href="https://www.benzinga.com/news/25/01/42995328/trump-inauguration-from-elon-musk-jeff-bezos-to-barack-obama-george-bush-and-bill-clinton-who-all-will-attend">before Trump&#8217;s inauguration</a>.
With a deadline looming, the app's fate lands in the hands of the so-called People's Bid for TikTok—backed by none other than Kevin O'Leary of &#8220;Shark Tank&#8221; and billionaire Frank McCourt. Apparently, TikTok's U.S. assets are still up for grabs, but no word yet on the price tag or whether a deal can realistically get done <a href="https://www.benzinga.com/general/social-media/25/01/43060894/supreme-court-upholds-tiktok-ban-ahead-of-trumps-inauguration">in a few days</a>.
<h2 class="wp-block-heading">Bankruptcy Block</h2>
Joann Inc. is stitching together a bankruptcy plan for the second time within 12 months. The Ohio-based fabric and crafts retailer is seeking a buyer for its portfolio of some 800 stores. 
Gordon Brothers Retail Partners emerged as the &#8220;stalking horse&#8221; bidder, but Joann remains hopeful for better offers—perhaps from someone who knows how to thread the needle.
Previously, the 82-year-old retailer was under the stewardship of private equity firm Leonard Green &amp; Partners, which acquired it via a $1.6 billion leveraged buyout in 2011. The firm buried the company under a pile of debt (<a href="https://wolfstreet.com/2024/03/18/brick-and-mortar-meltdown-fells-another-retailer-joann-inc-files-for-bankruptcy-3-years-after-ipo/">reportedly</a> $921 million in long-term debt as of Oct. 31, 2020) and <a href="https://www.benzinga.com/news/21/03/20048728/ipo-preview-roblox-coupang-joann-lead-busy-week-of-offerings">sent it public in 2021</a>. 
Joann went private again in <a href="https://apnews.com/article/joann-bankruptcy-chapter-11-filing-75093d4032907c59a45e472dd4e23229">March</a> 2024 while under Chapter 11 bankruptcy protection. The company managed to reduce its $1 billion total debt by about $500 million at the time.
Despite efforts to save itself last year, Joann is joining the growing quilt of recent retail casualties: Party City, Big Lots, LL Flooring, The Body Shop and The Container Store <a href="https://www.benzinga.com/news/legal/24/12/42710619/deal-dispatch-party-city-wraps-big-lots-goes-bust-container-store-continues">to name a few</a>.
Kirkland &amp; Ellis is handling legal matters, while Centerview Partners LLC offers financial advice. Alvarez &amp; Marsal North America, LLC is overseeing the restructuring process.
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Investment firm KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) hired Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to run an auction for its minority stake in Philippine fintech company Maya, Reuters reported. </li>
<li>New York-headquartered KKR owns more than 20% of Maya and the potential sale, if it goes through, could value Maya at more than $2 billion, one of the sources said.</li>
<li>DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is looking to <a href="https://www.benzinga.com/news/large-cap/25/01/43028181/chemical-company-dupont-electronics-business-separation-retains-water-business">jettison its electronics business</a>. The Wilmington, Delaware-based company expects the transaction to be completed by Nov. 1. DuPont also decided to retain its water business after evaluating strategic alternatives.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) is shopping its Performance Chemicals Industrial Specialties segment, which includes divesting parts of its North Charleston, South Carolina site. The company hopes to improve earnings cash flow and conclude the review process by year-end. Whether a transaction comes about <a href="https://www.benzinga.com/news/25/01/43027745/ingevity-explores-strategic-options-for-performance-chemicals-segment-to-strengthen-portfolio-projects-fy24-revenue-at-1-40-billion">remains to be seen</a>. </li>
<li>S&amp;W Seed Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANW#NASDAQ">SANW</a>) is up for sale. It&#8217;s also considering a merger or recapitalization as part of a larger strategic review. The Longmont, Colorado-based company has already sold its Australia subsidiary. &#8220;We continue to support all initiatives that optimize shareholder value and will consider the full range of potential strategic alternatives to ensure S&amp;W Seed is best positioned for future success,&#8221; chairman Alan Willits said.</li>
</ul>
See Also: <a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed">Starship Explodes During Flight Test, Elon Musk Says: &#8216;Success Is Uncertain, But Entertainment Is Guaranteed!&#8217;</a>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Lourenco Goncalves raised eyebrows during a Monday press conference. According to <a href="https://www.bloomberg.com/news/articles/2025-01-14/cliffs-ceo-rips-evil-japan-and-doubles-down-on-america-first">Bloomberg</a>, the CEO of Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) called Japan, a U.S. ally, &#8220;evil&#8221; and accused it of teaching China harmful practices like dumping and overproduction. His comments came as Cleveland-Cliffs eyes a new bid for U.S. Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>), following Biden&#8217;s decision to block Nippon Steel&#8216;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NPSCY#OTC">NPSCY</a>) <a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge">$14 billion acquisition attempt</a>. While positioning his company as a potential buyer, Goncalves&#8217; rhetoric escalated tensions within the steel industry. Nippon is now looking to Trump to <a href="https://www.benzinga.com/news/25/01/42994950/nippon-steel-eyes-trump-administration-to-revive-15b-us-steel-deal-blocked-by-biden-well-do-whatever-it-takes">help close the deal</a>. </li>
<li>T-Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) will buy Vistar Media for $600 million. The telecom company expects the deal to strengthen its advertising business, Reuters reported. </li>
</ul>
Deals in the biotech and pharmaceutical sectors piled up this week. Here&#8217;s a sample of Benzinga&#8217;s coverage:
<ul>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already own <a href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say">for $7.22 per share</a>. Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) <a href="https://www.benzinga.com/25/01/42950025/gsk-to-buy-us-based-stomach-cancer-drug-developer-for-over-1-billion">agreed to acquire</a> IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. The deal may require an additional $150 million from GSK after certain regulatory approval milestones. </li>
<li>Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) scooped up Scorpion Therapeutics&#8217; early-stage <a href="https://www.benzinga.com/25/01/42949261/eli-lilly-scoops-up-scorpion-therapeutics-early-stage-cancer-program-for-25-billion">cancer program for $2.5 billion</a>. </li>
<li>Like Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is seeking to bolster its neuropsychiatric portfolio<a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal"> with a $15 billion deal</a></li>
<li>Crown Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) offered to acquire all outstanding common shares of Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) at $3.10 per share.</li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) agreed to a deal with Decoy Therapeutics, a preclinical biotech focused on peptide conjugate therapeutics. The merged entity will target unmet needs in respiratory diseases and GI oncology.</li>
<li>Lantheus Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) strengthens its radiopharmaceutical position with<a href="https://www.benzinga.com/m-a/25/01/42937565/lantheus-strengthens-radiopharmaceutical-leadership-with-350m-acquisition-of-life-molecular-imaging"> $350 million acquisition of Life Molecular Imaging</a>.</li>
</ul>
For last week&#8217;s edition of Deal Dispatch, <a href="https://www.benzinga.com/ma/25/01/42921113/deal-dispatch-td-bank-charles-schwab-eyenovia-smart-share-hit-auction-block">click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/01/43055513/eccentric-billionaire-howard-hughes-former-miami-estate-on-market-for-55-5-million">Eccentric Billionaire, Legendary Filmmaker Howard Hughes&#8217; Former Miami Estate On Market For $55.5 Million</a></li>
</ul>
Image created with a photo from Shutterstock.

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt

<h3>Gainers</h3>
<ul>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock increased by 185.6% to $4.47 during Monday's pre-market session. The market value of their outstanding shares is at $6.4 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock moved upwards by 141.42% to $4.08. The market value of their outstanding shares is at $7.0 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock moved upwards by 69.84% to $2.14. The company's market cap stands at $8.5 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) stock increased by 38.01% to $7.66. The company's market cap stands at $468.5 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) stock moved upwards by 34.76% to $127.85. The market value of their outstanding shares is at $13.5 billion. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares rose 34.02% to $1.3. The market value of their outstanding shares is at $16.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock fell 31.4% to $4.1 during Monday's pre-market session. The company's market cap stands at $237.3 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares fell 27.47% to $0.59. The company's market cap stands at $2.9 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares decreased by 21.51% to $2.08. The market value of their outstanding shares is at $4.6 million. </li>
<li>Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares decreased by 21.02% to $33.37. The market value of their outstanding shares is at $12.8 billion. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock fell 19.4% to $1.33. The market value of their outstanding shares is at $39.3 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 19.19% to $0.15. The market value of their outstanding shares is at $11.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEON

AIRS

ATPC

DYAI

GTBP

ITCI

KAPA

MRNA

NAYA

PHIO

12 Health Care Stocks Moving In Monday's Pre-Market Session

Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) that it does not already owned by Biogen <a href="https://www.benzinga.com/25/01/42946734/why-is-depression-focused-sage-therapeutics-stock-surging-higher-on-monday" target="_blank" rel="noreferrer noopener">for $7.22 per share</a>.
Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the Zurzuvae launch for postpartum depression (PPD).
Biogen says Zurzuvae exceeded its expectations.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown" rel="noreferrer noopener">Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown</a>
Goldman Sachs estimates Zurzuvae could reach global peak sales of approximately $700 million for PPD by 2034.
Richter notes that investors remain focused on Biogen&#8217;s growth strategies. This includes expanding its pipeline, pursuing external business development, or leveraging new opportunities to counter declining revenue in the latter <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings" target="_blank" rel="noreferrer noopener">half of the decade</a>.
During the third quarter earnings call, management highlighted the potential for an $8 billion to $10 billion deal within the next two years, primarily focusing on rare diseases and immunology.
They also emphasized continued interest in neurology while acknowledging the strength of Biogen&#8217;s immunology capabilities from its multiple sclerosis franchise and the need to diversify further.
William Blair has consistently seen Zurzuvae&#8217;s role in treating postpartum depression as less significant to Biogen&#8217;s overall value. Instead, the firm prioritizes the progress of Biogen&#8217;s late-stage programs and improvements in Leqembi&#8217;s treatment profile.
Analyst Myles Minter suggests that while the deal may not boost Biogen&#8217;s stock, it provides a smart strategy for marketing Zurzuvae and maximizing its value.
If the deal is finalized, Biogen should consider acquiring more companies in the neuropsychiatry field to strengthen its collaboration with Zurzuvae, Minter says.
Price Action: Biogen stock is up 0.34% at $150.32 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42955324/cancer-focused-phio-pharmaceuticals-stock-gains-300-on-monday-heres-why" target="_blank" rel="noreferrer noopener">Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday &#8211; Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts

WIIM

Sage Therapeutics shares are trading higher after the company confirmed the receipt of an unsolicited, nonbinding proposal from Biogen to acquire all outstanding shares not already owned by Biogen for $7.22 per share.

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Monday.
The Dow traded up 0.13% to 41,992.95 while the NASDAQ dipped 1.42% to 18,888.78. The S&amp;P 500 also fell, dropping, 0.70% to 5,786.44.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/42944267/how-to-earn-500-a-month-from-fastenal-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Fastenal Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Energy shares rose by 2.2% on Monday.
In trading on Monday, utilities shares tumbled by 1.9%.
Top Headline 
Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) confirmed that Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares shot up 418% to $8.76 after the company reported promising results of second cohort from its ongoing clinical study of PH-762.</li>
<li>Shares of Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>)got a boost, surging 277% to $5.87. Salarius Pharmaceuticals and Decoy Therapeutics announced a definitive merger agreement.</li>
<li>Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) shares were also up, gaining 35% to $127.72 after Johnson &amp; Johnson agreed to acquire the company for $132.00 per share in cash for a total equity value of approximately $14.6 billion.</li>
</ul>
<ul>
<li>Equities Trading DOWN</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares dropped 22% to $33.13 after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below analyst estimates of $2.951 billion.</li>
<li>Shares of Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) were down 20% to $129.03 after issuing mixed fourth-quarter and FY24 guidance.</li>
<li>Comtech Telecommunications Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) was down, falling 47% to $2.1901 after the company announced downbeat quarterly results.</li>
</ul>
Commodities In commodity news, oil traded up 3.1% to $78.93 while gold traded down 1.1% at $2,685.60.
Silver traded down 3% to $30.37 on Monday, while copper rose 0.8% to $4.3365.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 0.45%, Germany's DAX 40 fell 0.26% and France's CAC 40 dipped 0.11%. Spain's IBEX 35 Index fell 0.23%, while London's FTSE 100 slipped 0.19%.
Asia Pacific Markets
Asian markets closed lower on Monday, with China's Shanghai Composite Index falling 0.25%, Hong Kong's Hang Seng Index declining 1% and India's BSE Sensex falling 1.36%.
Economics
Data on consumer inflation expectations will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42947348/tesla-to-rally-around-9-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CMTL

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge

U.S. stocks were mixed, with the Dow Jones index gaining over 200 points on Monday.
Shares of Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) rose sharply during Monday's session after Johnson &amp; Johnson agreed to acquire the company for $132.00 per share in cash for a total equity value of <a href="https://www.benzinga.com/general/biotech/25/01/42948170/like-bristol-myers-squibb-and-abbvie-johnson-johnson-seeks-to-bolster-neuropsychiatric-portfolio-with-15-billion-deal">approximately $14.6 billion</a>.
With this agreement, Johnson &amp; Johnson adds Intra-Cellular Therapies' Caplyta (lumateperone), a once-daily oral therapy approved to treat adults with schizophrenia, as well as depressive episodes associated with bipolar I or II disorder (bipolar depression), as a monotherapy and adjunctive therapy with lithium or valproate.
Intra-Cellular Therapies shares jumped 34.6% to $127.62 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares jumped 35.5% to $7.52. On Friday, Sage Therapeutics confirmed that Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.</li>
<li>Standard BioTools Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NYSE">LAB</a>) gained 24% to $2.0250 after the company announced preliminary fourth-quarter and FY24 financial results.</li>
<li>LSB Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) rose 21% to $9.00 after Piper Sandler upgraded the stock from Underweight to Overweight and raised its price target from $9 to $11.</li>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) gained 17% to $2.86.</li>
<li>SI-BONE, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) rose 14.1% to $15.66 after the company announced preliminary revenue for the fourth quarter and full year 2024.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) climbed 13.9% to $8.85.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) rose 13% to $39.92.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) climbed 12.2% to $6.00.</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) gained 11.4% to $6.93 as the company announced fourth-quarter preliminary revenue at high end of guidance.</li>
<li>Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) rose 10.4% to $96.43 after the company reported a year-over-year increase in FY24 AYVAKIT revenue results.</li>
<li>Radiopharm Theranostics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) gained 10.3% to $5.90. Radiopharm Theranostics announced it will execute a private placement and will raise $5 million in proceeds.</li>
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) gained 8.5% to $37.15 amid a report that Cleveland-Cliffs will partner with Nucor to make a potential bid for the company.</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) gained 6.6% to $286.90.</li>
<li>CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) rose 6.3% to $94.35. Piper Sandler analyst Charles Neivert upgraded CF Industries Holdings from Underweight to Overweight and raised the price target from $79 to $105.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42947348/tesla-to-rally-around-9-here-are-10-top-analyst-forecasts-for-monday">Tesla To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Monday</a></li>
</ul>

BPMC

CRML

RADX

SIBN

Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday

On Friday, Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) confirmed that&nbsp;Biogen Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of&nbsp;Sage Therapeutics&nbsp;not already owned by Biogen <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42930564/sage-therapeutics-confirms-receipt-of-unsolicited-nonbinding-acquisition-proposal-from-biogen" rel="noreferrer noopener">for&nbsp;$7.22&nbsp;per share</a>.
The Sage Board of Directors will carefully review and evaluate Biogen&#8217;s proposal.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42092122/after-failed-alzheimers-study-sage-therapeutics-dalzanemdor-flunks-another-study-in-patients-with-inherited-brain-disorder" rel="noreferrer noopener">After Failed Alzheimer&#8217;s Study, Sage Therapeutics&#8217; Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder</a>
In November 2020, Biogen and&nbsp;Sage Therapeutics executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.
The <a target="_blank" href="https://investors.biogen.com/news-releases/news-release-details/biogen-and-sage-therapeutics-announce-global-collaboration" rel="noreferrer noopener">deal</a> included an upfront payment of $875 million and a $650 million equity investment. Sage was also eligible to receive up to approximately $1.6 billion in potential milestone payments.
Over the last five years, Sage stock has slumped 90%.
In October last year, Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/b41376682/sage-therapeutics-announces-strategic-reorganization-to-prioritize-zurzuvae-commercialization-and-" rel="noreferrer noopener">in postpartum depression</a>.
The company said the reorganization was intended to strengthen Sage&#8217;s balance sheet, extend its cash runway, and position the company for long-term growth potential.
The company&#8217;s layoff impacted over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&amp;D workforce), including changes to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41382549/after-series-of-trial-setbacks-sage-therapeutics-to-lay-off-one-third-workforce" rel="noreferrer noopener">the leadership team</a>.
In September, Biogen terminated its rights under the collaboration and license agreement with Sage, which was specific to the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41049022/biogen-terminates-collaboration-with-sage-therapeutics-for-neurological-disorder-candidate" rel="noreferrer noopener">SAGE-324 program</a>.
Price Action: SAGE stock is up 37.3% at $7.62, and BIIB stock is down 0.25% at $148.45 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42939868/asia-and-europe-markets-in-red-lower-crude-oil-gains-dollar-strengthens-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">Asia And Europe Markets Fall, Dollar Hits New High &#8211; Global Markets Today While US Slept</a></li>
</ul>
Image via Shutterstock.

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

<h3>Gainers</h3>
<ul>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares increased by 81.0% to $2.28 during Monday's pre-market session. The company's market cap stands at $9.0 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares moved upwards by 36.93% to $7.6. The company's market cap stands at $464.9 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) shares rose 35.56% to $128.61. The company's market cap stands at $13.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock rose 32.73% to $0.16. The market value of their outstanding shares is at $2.4 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock moved upwards by 27.53% to $3.52. The market value of their outstanding shares is at $40.6 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares increased by 26.03% to $3.34. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) stock fell 14.7% to $7.0 during Monday's pre-market session. The company's market cap stands at $1.1 billion. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares declined by 13.69% to $0.82. The market value of their outstanding shares is at $9.8 million. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) shares decreased by 12.7% to $29.43. The market value of their outstanding shares is at $105.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock fell 12.49% to $0.61. The market value of their outstanding shares is at $2.9 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock declined by 12.21% to $5.25. The company's market cap stands at $303.8 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) stock declined by 12.11% to $0.71. The market value of their outstanding shares is at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGS

GCTK

GDTC

INDP

OCUL

Shares of Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) rose sharply in today's pre-market trading after the company confirmed the receipt of Biogen&#8217;s nonbinding $7.22/share <a href="https://www.benzinga.com/quote/SAGE">acquisition proposal</a>.
Sage Therapeutics shares jumped 34.2% to $7.45 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) gained 86.5% to $2.35 in pre-market trading after gaining 8% on Friday.</li>
<li>GlucoTrack, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) gained 62.3% to $0.1899 in pre-market trading after dipping over 15% on Friday.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) gained 47% to $0.1981 in pre-market trading after falling 18% on Friday.</li>
<li>Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) rose 29.3% to $10.45 in pre-market trading. Expert Systems and Traws Pharma reported a breakthrough in H5N1Bird Flu Antiviral Program.</li>
<li>Cooper-Standard Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPS#NYSE">CPS</a>) gained 26.3% to $16.69 in pre-market trading.</li>
<li>Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) gained 22.3% to $116.00 in pre-market trading after Bloomberg Reported that J&amp;J is exploring a bid for the company.</li>
<li>Black Diamond Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) gained 18.5% to $2.29 in pre-market trading following a 5% decline on Friday.</li>
<li>QMMM Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMMM#NASDAQ">QMMM</a>) gained 18% to $1.05 in pre-market trading.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) rose 14.1% to $15.75 in pre-market trading after reporting preliminary unaudited fourth quarter product revenue and full-year 2024 product revenues.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) fell 24.8% to $4.31 in pre-market trading after gaining 9% on Friday.</li>
<li>Vision Marine Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMAR#NASDAQ">VMAR</a>) fell 20.5% to $1.71 in today's pre-market trading after jumping 41% on Friday.</li>
<li>Direct Digital Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) fell 19.5% to $1.32 in pre-market trading after jumping around 38% on Friday.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) shares fell 18.6% to $0.8458 in pre-market trading after the company files for mixed shelf offering up to $100 million.</li>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) shares dipped 18.5% to $0.9624 in pre-market trading after declining around 14% on Friday.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) fell 17% to $7.41 in pre-market trading after dipping 11% on Friday.</li>
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) dipped 14.5% to $4.93 in pre-market trading.</li>
<li>ScanTech AI Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) shares fell 14.5% to $1.95 in pre-market trading after gaining around 5% on Friday.</li>
<li>Mercury General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) declined 13.4% to $42.00 in pre-market trading. Mercury General shares dipped around 20% on Friday after the company announced it anticipates wildfire losses in Southern California to surpass $150 million in reinsurance retention levels.</li>
<li>Tredegar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TG#NYSE">TG</a>) shares tumbled 8.1% to $6.82 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>

Pre-Market Outlook

ARQT

BDTX

DRCT

LAES

LDTC

QBTS

QMMM

RGTI

RIME

STAI

TRAW

VMAR

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket

Press Releases

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

Stocks to Watch in 2025: PHIO, LPTH, KAVL, Promising Innovations, Growth Opportunities, Etc. … more inside

Legal

Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition Proposal

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates

Comments

Sage Therapeutics

뉴스

에 대한 최신 뉴스 Sage Therapeutics (NASDAQ:SAGE) 주식

토요일, 2월 01, 2025

일요일, 1월 19, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌